Rani Therapeutics Holdings, Inc. Class A (RANI)

In November 2025, Rani Therapeutics released its Q3 2025 earnings, secured a collaboration agreement with Chugai Pharmaceutical Co., and announced funding, while its stock's price target was decreased. In October 2025, a director purchased shares, but the stock traded down due to investor concerns. In January 2026, Rani Therapeutics promoted Alireza Javadi to Chief Technical Officer, finalized governance changes, and initiated a Phase 1 clinical trial for RT-114. As of February 4, 2026, the share price decreased, but on February 6, 2026, the closing price increased. Over the past year, Rani Therapeutics has underperformed both the US Pharmaceuticals industry and the broader US Market.

As a clinical-stage biotherapeutics company, Rani Therapeutics does not have significant demand seasonality for its products and services. The company's revenue and progress are more likely tied to achieving developmental milestones, securing partnerships, and eventual product commercialization rather than seasonal consumer demand fluctuations.

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on revolutionizing drug delivery through its proprietary RaniPill capsule, an oral platform designed to administer large-molecule drugs that are traditionally given via injection. The company's core business revolves around its RaniPill capsule, a drug-agnostic oral delivery platform capable of delivering various drug substances, including oligonucleotides, peptides, proteins, and antibodies. The company's product pipeline includes RT-102, a parathyroid hormone in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody in preclinical studies for psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-111, an ustekinumab biosimilar for various inflammatory conditions; RT-114, a GLP-1/GLP-2 dual agonist for obesity, which initiated a Phase 1 clinical trial in January 2026, in collaboration with ProGen Co., Ltd; and RT-116, in the discovery stage for the treatment of obesity.

Rani Therapeutics Holdings, Inc. is headquartered in San Jose, California, United States, and primarily operates within the United States.

Rani Therapeutics generally maintains a positive brand reputation due to its innovative RaniPill platform, but its reputation has also been influenced by its financial performance. Negative events include missing Q3 2025 earnings estimates and the stock trading down in October 2025. Positive events include securing a collaboration agreement with Chugai Pharmaceutical Co. and the initiation of a Phase 1 trial for an oral obesity treatment in January 2026.

Institutional investors hold between 3.32% and 30.19% of Rani Therapeutics' stock, with major shareholders including Vanguard Group Inc and Nan Fung Group Holdings Ltd. Individual and insider ownership accounts for 33.62%, with Mir A. Imran being the largest individual shareholder. Retail investors constitute a significant portion of the ownership, holding between 63.06% and 65% of the company.